029-83533393
   info@TaiBSbio.com
 
组织芯片,组织微阵列
 
FOV961卵巢癌组织芯片,附病理分级、TNM和临床分期,48例/96点
Zoom
点 数96例 数48
行 数8列 数12
点直径(mm)1.0厚度(µm)5.0
组织阵列类型石蜡包埋种 属人类
QA/QCH&E and IHC confirmed
ApplicationsRoutine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.
Notes1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better.

2.Bake the slides for 30 minutes at 60℃ before the experiment;

3.Please choose a gentle repair method to avoid tissue detachment.

产品名:FOV961
 
卵巢癌组织微阵列芯片,含浆液性囊腺癌、粘液性囊腺癌、粘液腺癌、腺癌、子宫内膜样腺癌、透明细胞癌各6例,边缘组织12例,一例两点
 
 
询价  Tel: 029-83533393
 
下载说明书
 
 
Legend:
Ova
-Ovary
 
Malignant (*)
 
Malignant (I)
 
Malignant (IA)
 
Malignant (IB)
 
Malignant (IC)
 
Malignant (II)
 
Malignant (IIA)
 
Malignant (III)
 
Malignant (IIIA)
 
Malignant (IIIB)
 
Malignant (IIIC)
 
NAT (*)
TISSUE  ARRAYS FOV961
1
2
3
4
5
6
7
8
9
10
11
12
A
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
B
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
C
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
D
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
E
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
F
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
G
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
H
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
OVA
 
PosNoAgeSexOrgan_Anatomic_SitePathology_diagnosisGradeTNMStageTypeTumor SizeisBackUp
A1137FOvarySerous cystadenocarcinoma1T1N0M0IMalignant9*8*4.5N
A2243FOvarySerous cystadenocarcinoma3T2N0M0IIMalignant14*10*7N
A3351FOvarySerous papillary cystadenocarcinoma with sparse necrosis2T1aN0M0IAMalignant7*6*4N
A4441FOvarySerous papillary cystadenocarcinoma3T3aN0M0IIIAMalignant-N
A5553FOvarySerous papillary cystadenocarcinoma (sparse)3T3bN0M0IIIBMalignant9*6.5*3.0N
A6643FOvarySerous cystadenocarcinoma3T3N0M0IIIMalignant0.2N
A7743FOvaryMucinous cystadenocarcinoma2T3cN0M0IIICMalignant11*6*4N
A8841FOvaryMucinous cystadenocarcinoma2T2aN0M0IIAMalignant12*10*4N
A9964FOvaryMucinous cystadenocarcinoma2T1aN0M0IAMalignant-N
A101048FOvaryMucinous cystadenocarcinoma2T3cN0M0IIICMalignant15*12*8N
A111148FOvaryMucinous cystadenocarcinoma3T3cN1M0IIICMalignant15*12*8N
A121261FOvaryMucinous cystadenocarcinoma3T1cN0M0ICMalignant-N
B11337FOvarySerous cystadenocarcinoma1T1N0M0IMalignant9*8*4.5N
B21443FOvarySerous cystadenocarcinoma3T2N0M0IIMalignant14*10*7N
B31551FOvarySerous papillary cystadenocarcinoma2T1aN0M0IAMalignant7*6*4N
B41641FOvarySerous papillary cystadenocarcinoma3T3aN0M0IIIAMalignant-N
B51753FOvarySerous papillary cystadenocarcinoma3T3bN0M0IIIBMalignant9*6.5*3.0N
B61843FOvarySerous cystadenocarcinoma3T3N0M0IIIMalignant0.2N
B71943FOvaryMucinous cystadenocarcinoma2T3cN0M0IIICMalignant11*6*4N
B82041FOvaryMucinous cystadenocarcinoma with necrosis (sparse)2T2aN0M0IIAMalignant12*10*4N
B92164FOvaryMucinous cystadenocarcinoma2T1aN0M0IAMalignant-N
B102248FOvaryMucinous cystadenocarcinoma2T3cN0M0IIICMalignant15*12*8N
B112348FOvaryMucinous cystadenocarcinoma3T3cN1M0IIICMalignant15*12*8N
B122461FOvaryMucinous cystadenocarcinoma3T1cN0M20ICMalignant-N
C12554FOvaryMucinous adenocarcinoma1T1bN0M0IBMalignant-N
C22634FOvaryMucinous adenocarcinoma with necrosis (sparse)1T1bN0M0IBMalignant-N
C32735FOvaryMucinous adenocarcinoma2T1bN0M0IBMalignant-N
C42840FOvaryMucinous adenocarcinoma (interstitial)3T1aN0M0IAMalignant7*4*3N
C52950FOvaryMucinous adenocarcinoma3T2N0M0IIMalignant7*4*4N
C63045FOvaryMucinous adenocarcinoma3**Malignant-N
C73155FOvaryAdenocarcinoma3T1aN0M0IAMalignant-N
C83260FOvaryAdenocarcinoma3T3cN0M0IIICMalignant-N
C93348FOvaryAdenocarcinoma3T1aN0M0IAMalignant-N
C103444FOvaryAdenocarcinoma3T3bN0M0IIIBMalignant-N
C113565FOvaryAdenocarcinoma3T1aN1M0IIICMalignant-N
C123647FOvaryAdenocarcinoma4T1cN0M0ICMalignant7*5*3N
D13754FOvaryMucinous adenocarcinoma1T1bN0M0IBMalignant-N
D23834FOvaryMucinous adenocarcinoma1T1bN0M0IBMalignant-N
D33935FOvaryMucinous adenocarcinoma2T1bN0M0IBMalignant-N
D44040FOvaryMucinous adenocarcinoma3T1aN0M0IAMalignant7*4*3N
D54150FOvaryMucinous adenocarcinoma3T2N0M0IIMalignant7*4*4N
D64245FOvaryMucinous adenocarcinoma3**Malignant-N
D74355FOvaryAdenocarcinoma3T1aN0M0IAMalignant-N
D84460FOvaryAdenocarcinoma3T3cN0M0IIICMalignant-N
D94548FOvaryAdenocarcinoma3T1aN0M0IAMalignant-N
D104644FOvaryAdenocarcinoma3T3bN0M0IIIBMalignant-N
D114765FOvaryAdenocarcinoma3T1aN1M0IIICMalignant-N
D124847FOvaryAdenocarcinoma4T1cN0M0ICMalignant7*5*3N
E14954FOvaryEndometrioid adenocarcinoma1T1cN0M0ICMalignant18*13*8N
E25033FOvaryEndometrioid adenocarcinoma2T1N0M0IMalignant-N
E35155FOvaryEndometrioid adenocarcinoma2--3T1cN0M0ICMalignant-N
E45230FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
E55355FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
E65458FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
E75553FOvaryClear cell carcinoma2T1bN0M0IBMalignant10*7*2N
E85642FOvaryClear cell carcinoma (necrosis)*T1aN0M0IAMalignant9.5*5*1N
E95740FOvaryClear cell carcinoma2T3cN0M0IIICMalignant-N
E105843FOvaryClear cell carcinoma2T1aN0M0IAMalignant7*4*3N
E115954FOvaryClear cell carcinoma3T3aN0M0IIIAMalignant-N
E126061FOvaryClear cell carcinoma3T1aN0M0IAMalignant12*6*6N
F16154FOvaryEndometrioid adenocarcinoma1T1cN0M0ICMalignant18*13*8N
F26233FOvaryEndometrioid adenocarcinoma2T1N0M0IMalignant-N
F36355FOvaryEndometrioid adenocarcinoma2--3T1cN0M0ICMalignant-N
F46430FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
F56555FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
F66658FOvaryEndometrioid adenocarcinoma3T1aN0M0IAMalignant-N
F76753FOvaryClear cell carcinoma2T1bN0M0IBMalignant10*7*2N
F86842FOvaryClear cell carcinoma2T1aN0M0IAMalignant9.5*5*1N
F96940FOvaryClear cell carcinoma2T3cN0M0IIICMalignant-N
F107043FOvaryClear cell carcinoma2T1aN0M0IAMalignant7*4*3N
F117154FOvaryClear cell carcinoma3T3aN0M0IIIAMalignant-N
F127261FOvaryClear cell carcinoma3T1aN0M0IAMalignant12*6*6N
G17336FOvaryAdjacent normal ovary tissue***NAT-N
G27448FOvaryAdjacent normal ovary tissue***NAT-N
G37554FOvaryAdjacent normal ovary tissue***NAT-N
G47664FOvaryAdjacent normal ovary tissue***NAT-N
G57752FOvaryAdjacent normal ovary tissue***NAT-N
G67848FOvaryAdjacent normal ovary tissue***NAT-N
G77957FOvaryAdjacent normal ovary tissue***NAT-N
G88051FOvaryAdjacent normal ovary tissue***NAT-N
G98150FOvaryAdjacent normal ovary tissue***NAT-N
G108235FOvaryAdjacent normal ovary tissue***NAT-N
G118342FOvaryAdjacent normal ovary tissue***NAT-N
G128451FOvaryAdjacent normal ovary tissue***NAT-N
H18536FOvaryAdjacent normal ovary tissue***NAT-N
H28648FOvaryAdjacent normal ovary tissue***NAT-N
H38754FOvaryAdjacent normal ovary tissue***NAT-N
H48864FOvaryAdjacent normal ovary tissue***NAT-N
H58952FOvaryAdjacent normal ovary tissue***NAT-N
H69048FOvaryAdjacent normal ovary tissue***NAT-N
H79157FOvaryAdjacent normal ovary tissue***NAT-N
H89251FOvaryAdjacent normal ovary tissue***NAT-N
H99350FOvaryAdjacent normal ovary tissue***NAT-N
H109435FOvaryAdjacent normal ovary tissue***NAT-N
H119542FOvaryAdjacent normal ovary tissue***NAT-N
H129651FOvaryAdjacent normal ovary tissue***NAT-N
Tissue Marker
 
 
西安泰博斯生物科技有限公司

 
联系我们
地址:陕西西安市灞桥区长乐东路2999号
电话:029-83533393, 17792711553,
电子邮箱:taibsbio@163.com
QQ:3144647811
微信号:13002913390
邮政编码:710075
关于我们
西安泰博斯生物科技有限公司主要经营组织芯片的研发、销售,加工定制和与组织芯片有关的生物技术服务项目。公司目前拥有专业的病理医生和技术研发团队,并且具有庞大的组织标本库。样本库中组织微阵列种类多,病理类型齐全,同时根据客户需求情况进行制作加工新的组织微阵列,尽量满足每一个客户的需求。公司一直秉承着“认真、严谨、负责”的工作态度,致力于为广大客户提供质量好的产品和优质的服务。

更多详情